SCHEMBL24309877

SCHEMBL24309877

Cc1ccccc1Oc1nc(NS(=O)(=O)c2cnn(C)c2)nc(-c2ccccc2C)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 7/20 0.42
▸ HTR7 P34969 7/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ DRD2 P14416 3/20 0.36
▸ HTR6 P50406 1/20 0.36
▸ THRB P10828 1/20 0.35
▸ HTR2A P28223 2/20 0.34
▸ MAP3K7 O43318 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ MAP2K1 Q02750 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ MALT1 Q9UDY8 1/20 0.33
▸ PTPN11 Q06124 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566904 1.00 HTR1A (0.42) HTR1AHTR7SMN1; SMN2HIF1ADRD2
SCHEMBL24309827 0.90 HTR1A (0.43) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29566900 0.90 HTR1A (0.43) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29566814 0.89 HTR1A (0.42) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24309825 0.89 HTR1A (0.42) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29567189 0.89 HTR1A (0.42) HTR1AHTR7SMN1; SMN2HIF1ADRD2
SCHEMBL24310178 0.89 HTR1A (0.42) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24309396 0.89 HTR1A (0.42) HTR1AHTR7SMN1; SMN2HIF1ADRD2
SCHEMBL29567180 0.89 HTR1A (0.42) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24310357 0.88 HTR1A (0.41) HTR1AHTR7DRD2HTR6THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HTR1A 4018/4885HTR7 3833/4885SMN1; SMN2 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback